GeneNews company
GeneNewsâ„¢ is a molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic tests for early disease detection, determining the stage of disease and monitoring its progression, treatment or recurrence. Tests based on the company's Sentinel Principleâ„¢ are being developed in the areas of cancer, cardiovascular diseases, psychiatric disorders, central nervous system diseases and arthritis. The company's lead product in its Sentry line of blood tests is ColonSentry, a test for colorectal cancer screening that is commercially available in Ontario.
Technology:
P4 Medicine
Industry:
Biotechnology, Health Care, Science and Engineering
Headquarters:
Richmond Hill, Ontario, Canada
Founded Date:
1998-01-01
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
28
Total Funding:
$51.9M
Estimated Revenue:
Less than $1M
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership